India: Healthcare

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
Right To Know Prevails Over Scientific Uncertainty: Madras High Court Upholds Microplastics Labelling Requirement
In a significant ruling between Food Safety and Standards Authority of India v. G. Subramania Koushik & Ors. addressing consumer awareness and food safety, the Madras High Court has upheld its earlier directions requiring precautionary labelling on plastic/PET-bottled drinking water and sugar and salt sold in plastic packaging, indicating the possible presence of microplastics and nanoplastics. The decision highlights the importance of consumer disclosure, particularly where scientific research has identified potential health concerns but the precise extent of the associated risks remains under investigation.
India Consumer
IL
IndiaLaw LLP
Article
Life Sciences And Healthcare Newsletter | June 2026
India's life sciences and healthcare sector continues to evolve through significant regulatory and policy developments in June 2026. Key changes include pharmacovigilance mandates, prohibition of irrational drug combinations, expanded QR code authentication requirements, cosmetics compliance directions, ART and surrogacy clinic renewal frameworks, safe injection practice mandates, drug price control reforms, and new ambulance service guidelines that reshape pharmaceutical, biotechnology, medical devices, an
India Healthcare
DL
Dentons Link Legal
Article
Delhi High Court Grants ₹3.34 Crore Damages To Johnson & Johnson In Counterfeit Medical Devices Case
The Hon’ble Delhi High Court has granted a permanent injunction in favour of the American pharmaceutical and medical devices giant Johnson & Johnson (“J&J”), restraining a New Delhi-based entity from infringing its trademarks ‘Surgicel’, ‘Ligaclip’ and ‘Ethicon’, and from manufacturing, distributing, or selling counterfeit surgical devices. Recognising the grave public health risks posed by counterfeit medical products, the Court also awarded damages amounting to approximately ₹3.34 crore against the defendants.
India IP
SR
S.S. Rana & Co. Advocates
See more